Design Therapeutics, Inc.

DSGN

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0001807120

SEC filings (opens in a new tab)

No open-market purchases or sales by Design Therapeutics, Inc. insiders were filed in the last 90 days; 136 institutions reported holding it in 13F filings for Q2 2026, worth $626.4M in total; no superinvestor holds it.

Q3 2021 vs. Q2 2021

How the institutions holding Design Therapeutics, Inc. changed between Q2 2021 and Q3 2021.

All holders in Q3 2021 All holders in Q2 2021

13F holders of DSGN: Q2 2021 compared with Q3 2021
Measure	Q2 2021	Q3 2021	Change
Holders	50	52	+2
Shares	27.8M	28.3M	+442.2K (+1.6%)
Value	$546.2M	$414.8M	−$131.4M (−24.1%)

New holders (3)

Institutions that held Design Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.

Institutions new to DSGN in Q3 2021
Institution	Shares	Value	% of portfolio
Millennium Management LLC	14,169	$208.0K	0.00%
Rhumbline Advisers	10,589	$156.0K	0.00%
Piper Sandler & Co.	2,500	$37.0K	0.05%

Sold out (1)

Institutions that held Design Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.

Institutions that sold out of DSGN in Q3 2021
Institution	Shares, Q2 2021	Value, Q2 2021
Pinz Capital Management, LP	4,338	$86.0K